FindTrial
Sign In

A Retrospective Study of Tranexamic Acid for Reducing Intraoperative Blood Loss in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer

A Retrospective Study of Tranexamic Acid for Reducing Intraoperative Blood Loss in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124449
Enrollment
Unknown
Registered
2026-05-12
Start date
2026-05-12
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

Patients with advanced ovarian cancer:None

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1.Adult women aged 20 to 80 who were diagnosed with advanced ovarian cancer and underwent cell reduction surgery; 2.ASA II-III;

Exclusion criteria

Exclusion criteria: 1.Kidney dysfunction or liver dysfunction; 2.Having severe mental illness or mental disorders, a history of epilepsy, visual impairment, etc. 3.Previous or current presence of bleeding disorders, coagulation dysfunction or thromboembolic events; 4.The anticoagulant or antifibrinolytic drugs used before the operation and those used within the last month; 5.Allergic to TXA;

Design outcomes

Primary

MeasureTime frame
Hospitalization period;Bleeding;—

Countries

China

Contacts

Public ContactXu Pingbo

Zhejiang Cancer Hospital

xupingboshanghai@163.com+86 18017312996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026